Gulf International Bank UK Ltd Sells 155 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Gulf International Bank UK Ltd lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.1% in the 4th quarter, HoldingsChannel reports. The firm owned 14,504 shares of the medical research company’s stock after selling 155 shares during the quarter. Gulf International Bank UK Ltd’s holdings in IQVIA were worth $2,850,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in IQV. FMR LLC lifted its stake in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in IQVIA during the third quarter worth about $147,683,000. JPMorgan Chase & Co. lifted its stake in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Nordea Investment Management AB increased its holdings in shares of IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares during the period. Finally, KBC Group NV increased its holdings in shares of IQVIA by 68.5% in the fourth quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock worth $121,109,000 after buying an additional 250,458 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 1.3 %

IQV stock opened at $188.89 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $184.66 and a fifty-two week high of $261.73. The business’s 50 day moving average price is $199.13 and its two-hundred day moving average price is $214.96. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market capitalization of $33.26 billion, a price-to-earnings ratio of 25.19, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Transactions at IQVIA

In related news, Director John G. Danhakl purchased 1,275 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The shares were purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the transaction, the director now directly owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on IQV. Barclays decreased their price objective on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Stifel Nicolaus decreased their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft decreased their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Morgan Stanley boosted their price target on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Finally, Leerink Partners restated an “outperform” rating and set a $248.00 price target (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Four research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $251.22.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.